Meta-analysis of N-Acetylcysteine to Prevent Acute Renal Failure After Major Surgery
Background
Acute renal failure after major surgery is associated with significant mortality and morbidity that theoretically may be attenuated by N-acetylcysteine.
Design
Meta-analysis of relevant studies sourced from the Cochrane Controlled Trial Register (2007 issue 4), EMBASE, and MEDLINE databases (1966 to February 1, 2008) without language restriction.
Setting & Population
Adult patients undergoing major surgery without the use of radiocontrast.
Selection Criteria for Studies
Randomized controlled studies comparing N-acetylcysteine with a placebo perioperatively.
Data Analysis
Categorical variables are reported as odds ratio (OR) with 95% confidence interval (CI), and continuous variables are reported as weighted-mean-difference (WMD) with 95% CI.
Outcome Measures
Effects of N-acetylcysteine on mortality and acute renal failure requiring dialysis were the main outcomes of interest. Additional outcome measures included an incremental increase in serum creatinine concentration greater than 25% above baseline, surgical reexploration for bleeding, amount of allogeneic blood transfusion, and length of intensive care unit stay.
Results
10 studies involving a total of 1,193 adult patients undergoing major surgery were considered. N-Acetylcysteine use was not associated with a decrease in mortality (OR, 1.05; 95% CI, 0.58 to 1.92), acute renal failure requiring dialysis (OR, 1.04; 95% CI, 0.45 to 2.37), incremental increase in serum creatinine concentration greater than 25% above baseline (OR, 0.84; 95% CI, 0.64 to 1.11), or length of intensive care unit stay (WMD in days, 0.46; 95% CI, −0.43 to 1.36). N-Acetylcysteine did not appear to increase the risk of surgical reexploration for bleeding (OR, 1.16; 95% CI, 0.57 to 2.38) or amount of allogeneic blood transfusion required (WMD in units, 0.31; 95% CI, −0.21 to 0.84).
Limitations
Most studied patients had cardiac surgery and normal renal function preoperatively.
Conclusions
There is no current evidence that N-acetylcysteine used perioperatively can alter mortality or renal outcomes when radiocontrast is not used.
Index Words: Length of stay, mortality, renal dysfunction, renal protection
To access this article, please choose from the options below
Originally published online as doi:10.1053/j.ajkd.2008.05.019 on July 25, 2008.
PII: S0272-6386(08)00958-X
doi:10.1053/j.ajkd.2008.05.019
© 2008 National Kidney Foundation, Inc. Published by Elsevier Inc All rights reserved.
